BioInsights - Utilizing AI to drive AAV-based gene delivery to the CNS

Utilizing AI to drive AAV-based gene delivery to the CNS

Cell & Gene Therapy Insights 2023 9(4), 495–502

DOI: 10.18609/cgti.2023.072

Published: 30 May
Interview
David Huss


Artificial intelligence and machine learning are entering an era of practical application in the cell and gene therapy space—with exciting early results. David McCall, Senior Editor, BioInsights, speaks to David Huss, Chief Scientific Officer, Shape Therapeutics, about ShapeTX’s application of AI across the organization, from novel AAV capsid discovery and development to honing core business practices.